Elanco Animal Health (ELAN) Non-Current Deferred Tax Liability (2017 - 2026)
Elanco Animal Health (ELAN) reported Non-Current Deferred Tax Liability of $366.0 million for Q1 2026, down 23.91% on a YoY basis from $481.0 million in Q1 2025, and down 4.19% sequentially from $382.0 million in Q4 2025.
Elanco Animal Health (ELAN) Non-Current Deferred Tax Liability (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $366.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 23.91% year-over-year to $366.0 million; the trailing twelve-month figure through Mar 2026 stood at $366.0 million (down 23.91% YoY), and the FY2025 full-year result was $382.0 million, down 14.92% from the prior year.
- Non-Current Deferred Tax Liability retreated to $366.0 million in Q1 2026, from $382.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 billion in Q4 2022 to a low of $366.0 million in Q1 2026.
- A 5-year average of $578.4 million and a median of $539.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 40.13% in 2022 and tumbled 47.11% in 2023, its largest moves.
- Tracing ELAN's Non-Current Deferred Tax Liability over 5 years: stood at $1.1 billion in 2022, then tumbled by 47.11% to $567.0 million in 2023, then decreased by 20.81% to $449.0 million in 2024, then retreated by 14.92% to $382.0 million in 2025, then fell by 4.19% to $366.0 million in 2026.
- Business Quant data shows ELAN's Non-Current Deferred Tax Liability at $366.0 million in Q1 2026, $382.0 million in Q4 2025, and $478.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 366.00 Mn |
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 382.00 Mn |
| Dec 31, 2025 | 382.00 Mn |
| Sep 30, 2025 | 478.00 Mn |
| Sep 30, 2025 | 478.00 Mn |
| Jun 30, 2025 | 496.00 Mn |
| Jun 30, 2025 | 496.00 Mn |
| Mar 31, 2025 | 481.00 Mn |
| Mar 31, 2025 | 481.00 Mn |
| Dec 31, 2024 | 449.00 Mn |
| Dec 31, 2024 | 449.00 Mn |
| Sep 30, 2024 | 539.00 Mn |
| Sep 30, 2024 | 539.00 Mn |
| Jun 30, 2024 | 524.00 Mn |
| Jun 30, 2024 | 524.00 Mn |
| Mar 31, 2024 | 530.00 Mn |
| Mar 31, 2024 | 530.00 Mn |
| Dec 31, 2023 | 567.00 Mn |
| Dec 31, 2023 | 567.00 Mn |